

Reference	Reason for exclusion
Fisher 2000 ⁶⁵	Short report to Negro <i>et al.</i> ⁶⁶
Grigorescu 2002 ⁶⁷	Quasi-randomised
Lin 2002 ⁶⁸	Not a RCT
Georgoulas 2003 ⁶⁹	Interim analysis (not complete patient sample) to Georgoulas <i>et al.</i> ⁷⁰
Leong 2003 ⁷¹	Amifostine (cytoprotective adjuvant used in cancer CTX and RT; indication for NSCLC withdrawn 2005)
Miller 2003 ⁷²	Dosing study using sequentially enrolled cohorts
Semrau 2003 ⁷³	No English abstract
Teng 2003 ^{74a}	Not a RCT
Vansteenkiste 2003 ⁷⁵	Detailed individual symptom control analysis and the influence of CIS use, age, PS and duration of treatment of Vansteenkiste <i>et al.</i> ⁷⁶
O'Brien 2004 ⁷⁷	PLAT-based CTX with or without SRL172 (killed <i>Mycobacterium vaccae</i> suspension)
Gao 2005 ^{78a}	Unclear if patients were CTX naive
Liu 2006 ^{79a}	Unclear if patients were CTX naive
Ramalingam 2006 ⁸⁰	Subanalysis by age of Belani <i>et al.</i> ⁸¹ (not randomised by age)
Xu 2006 ^{82a}	Does not report survival (only response rates and AEs)
Gridelli 2007 ⁸³	Rofecoxib (withdrawn)
Gridelli 2008 ⁸⁴	No outcome data – rationale and protocol only
Zhang 2008 ^{85a}	Unclear if patients were CTX naive

a Required translation – abstract English.